Introduction
The possibility that non-angiotensin-convertingenzyme (ACE) pathways contribute to angiotensin II (Ang II) generation in the heart, large arteries, and the kidney has been explored in a growing number of studies, largely in vitro and in animal models. [1] [2] [3] [4] [5] [6] [7] [8] [9] These studies have suggested a wide range in the percentage of Ang II generated locally via the non-ACE pathway. In the case of the human kidney studied in vivo, we found that about 40% of Ang II generated locally could be attributed to the non-ACE pathway. These studies were performed in normal humans who were in balance on a low-salt diet, to activate the renin system, and compared the relative renal vasodilator response to ACE inhibition to the response to renin inhibition and Ang II antagonists as the index of non-ACE Ang II generation. 10 In this study, we have used that measure of non-ACE Ang II generation to examine the influence of salt intake on these renal pathways. The specific hypothesis that we tested was that salt intake influences solely renin production, and so the ACE and the non-ACE pathways for Ang II generation would be influenced similarly by a change in salt intake. The data made it necessary to reject this simple hypothesis.
Methods

Subjects and protocols
We performed 73 studies in 65 lean, healthy men and women who ranged in age from 19 to 49 years. All were free from cardiovascular, renal, and endocrine diseases and all were studied during admission to a metabolic ward at the General Clinical Research Center (GCRC) at the Brigham and Women's Hospital, where sodium balance was achieved on a controlled diet. The protocol was approved by the Human Subjects Committee of the institution, and written informed consent was obtained from each subject. Data on some of these subjects has been previously reported, [10] [11] [12] [13] but the analyses here are original.
Of the 73 studies, 41 were performed on a lowsalt isocaloric diet starting two days prior to admission and continuing throughout the 5-8 day hospitalisation period, with a daily sodium intake of 10 mmol. The other 32 studies were performed on an identical diet but containing 200 mmol sodium/ day. Daily dietary potassium (100 mmol) and fluid intake (2500 mL) were constant. Twenty-four hour urine samples were collected daily and analysed for sodium, potassium, and creatinine content. When external sodium balance was achieved, in 3-7 days, the first study was initiated.
On the morning of the study day, an intravenous catheter was placed in each arm, one for paraaminohippurate (PAH) and inulin infusion and the other for blood sampling. 11 The subjects were supine and had been fasting for at least 8 hours. Each study day began with a 60-minute baseline infusion of PAH and inulin prior to drug administration, to determine renal plasma flow (RPF) and glomerular filtration rate (GFR) respectively. At 0800 hours, the subjects were given either candesartan 16 mg or captopril 25 mg. The renal haemodynamic response was then monitored for four additional hours, with blood samples collected at 45 minute intervals. Both the captopril and the candesartan doses employed in this study have been shown to lie at the top of the dose-response relationship for the renal blood supply. 10, 13 Blood pressure (BP) was recorded during each infusion by an automatic recording device (Dinamap, Critikon) at 5-minute intervals.
Renal clearance studies PAH (Merck, Sharp & Dohme) and inulin (Inutest; Fresenius Pharma Austria GmbH) clearances were assessed after metabolic balance had been achieved. A control blood sample was drawn, then loading doses of PAH (8 mg/kg) and inulin (50 mg/kg) were given intravenously. A constant infusion of PAH and inulin was initiated immediately at a rate of 12 mg/minute and 30 mg/minute, respectively, with an IMED pump (IMED Corp.). This achieved a plasma PAH concentration in the middle of the range in which tubular secretion dominates excretion. At this plasma level of PAH, clearance is independent of plasma concentration, and represents about 90% of renal plasma flow when corrected for individual body surface area. Likewise, at the level of plasma inulin achieved, inulin clearance reflects glomerular filtration. RPF and GFR determinations were made at baseline and at 45-minute intervals thereafter until 225 minutes (approximately 4 hours).
Laboratory procedures
Blood samples were collected on ice and spun immediately, and the plasma was frozen until assay. Urinary sodium and serum potassium levels were measured using the ion selective electrode (ISE). PAH and inulin were measured using an autoanalyser technique. Plasma renin activity (PRA) was measured by radioimmunoassay. 14
Analyses
Group means were calculated with the standard error of the mean (SEM) as the index of dispersion. For renal haemodynamic data, the baseline value taken was the average of three pre-drug determinations, and the peak response was the average of the two highest consecutive values. The t-test and Wilcoxon Rank Sum Test were used to compare renal vascular responses to candesartan and captopril.
Results
The four groups of subjects studied, divided into cohorts according to salt intake and the drug received, were well matched with regard to age, gender distribution, height, weight, body mass index, and renal function, as exemplified by serum creatinine concentration and glomerular filtration rate ( Table 1 and Table 2 ). They were also comparable from the point of view of baseline renal plasma flow (Table 2) . Salt intake restriction produced the anticipated fall in sodium excretion and increase in recumbent PRA at baseline (Table 1) . Again, the rise in PRA and fall in urine sodium concentration was comparable in both groups studied on a low-salt diet.
The renal haemodynamic response to blockade of the renin system, however, varied according to the agent used. On a low-salt diet, the response to candesartan (165±14 ml/min/1.73 m 2 ) substan-tially exceeded the response to captopril on the same diet (118±12 ml/min/1.73 m 2 ; p<0.025), as anticipated from earlier reports 10 (Figure 1) .
On a high-salt diet, an even more striking difference appeared. The subjects who received candesartan showed a response (97±20 ml/min/1.73 m 2 ), significantly greater than the response to captopril (30±15 ml/min/1.73 m 2 ; p<0.01). The responses of glomerular filtration rate were not significant, and so changes in filtration fraction paralleled changes in RPF.
In the six subjects that received both candesartan and captopril on the same diet, there was striking concordance in the responses to the two agents (r=0.86; F=11.83; p<0.001). In this subset, the response to candesartan (140±43 ml/min/1.73 m 2 ) also significantly exceeded the response to captopril (81±23 ml/min/1.73 m 2 ; p<0.05). The average values are intermediate as half the subjects were studied on a low-salt diet, and the other half on a high-salt diet.
Discussion
The estimates of the contribution of non-ACE pathways to total Ang II generation in various tissues have shown a wide range. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] In part, this range probably reflects the fact that different approaches and different techniques have been applied to the problem. Another possible contributor, explored in this study, was that the physiological state also contributed to the relative contribution of ACE and non-ACE-dependent pathways. As sodium intake plays such a crucial role in determining the state of the renin system, this study was designed to explore salt intake as an influence on the two pathways. As anticipated, the RPF response to both agents was reduced substantially on a high-salt diet. Indeed, the reduction in response on a high-salt diet was sufficiently similar on the two agents to suggest that only the ACE pathway contributed to the reduced response. As a consequence, the contribution of the non-ACE pathway rose from 30-40% on a lowsalt diet to 60-70% on a high-salt diet. The findings were not in accordance with the simple hypothesis that salt influenced solely renin production and release, so that the ACE and non-ACE pathways show similar relative changes.
As many of these renal haemodynamic studies were performed in different individuals, their comparability is a crucial issue. All were healthy, relatively young, lean, and Caucasian. Basal RPF, prior to administration of either candesartan or captopril, was essentially identical in all four subgroups. The groups were also comparable at baseline in all of the measured indices, including urine sodium and PRA. Thus, it is unlikely that endogenous baseline differences contributed to the difference in response. Although a preferable study design would have involved studying the same individuals' response to both agents, and on both diets, this study design was not possible for two reasons. First, the volume of blood required for the protocol precluded four study days. Secondly, the duration of such a study would make recruiting difficult. Two other issues are relevant to interpretation of the data.Were the doses at the maximum of the dose-response relationship? Did the time course of our measurements include the time at which the peak response is achieved? The answer to both is yes. In our earlier study, we made a substantial investment showing that the peak renal haemodynamic response to candesartan occurred within 3-4 hours of administration. 13 The dose of both captopril and candesartan was chosen to lie at the top of the dose-response relationship for the kidney. [10] [11] [12] [13] Thus, differences cannot be attributed to either the use of either an inadequate dose or measurements made at the wrong time point.
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The magnitude of the shift from ACE to non-ACE pathways came as a surprise. The percentage reduction in the renal vascular response to captopril was substantially larger than the percentage reduction in the response to candesartan. The absolute difference between the response to captopril and candesartan was maintained. If the striking reduction in response to captopril reflected a fall in intrarenal Ang II, one would have anticipated a similar fall in the response to candesartan. On a low-salt diet, the renal vascular response to renin inhibition and to the Ang II antagonist is essentially identical, indicating that all of the Ang II formation is renin-dependent. 10 Thus, the striking fall in the response to captopril must reflect factors beyond a reduction in tissue or plasma renin activity. The only available explanation lies at the ACE level.
In cultured bovine endothelial cells,ACE activity is under hormonal control, being decreased by insulin and increased by glucocorticoids and thyroid hormone. 15 ACE activity has been reported to be induced by exposure to ACE-I in vivo 16 and in vitro. 17 In rats in vivo, Schunkert et al. 18 demonstrated feedback inhibition of Ang II on ACE mRNA activity. In rats, ACE inhibition upregulated ACE mRNA expression and ACE activity and, conversely, intravenous Ang II downregulated both.
There are other data which suggest that intrarenal ACE may be especially sensitive to salt intake. In studies designed to examine intrarenal ACE function by measuring the renal haemodynamic response to intravenous Ang I in subjects on a high-salt diet, it appeared that ACE in the kidney made a trivial contribution to total Ang II generation. 19, 20 Conversely, in studies on a low-salt diet, PAPER renal ACE appeared to make a substantial contribution to intrarenal Ang II formation. 10 Although the underlying mechanism remains unclear, the possibility that ACE gene expression and its regulation by salt intake plays a role must be considered. 21 An alternative to the hypothesis that the difference between the response to candesartan and to captopril reflects non-ACE pathways for Ang II generation is difficult to identify. One alternative, that the increased response to the Ang II antagonist reflects an action unrelated to Ang II, is possible, but is made very unlikely by the striking concordance identified earlier in responses to renin inhibitors and to an Ang II antagonist. 10 That concordance strongly suggests that the action of both classes of agent reflects a dominant, if not sole, action on the renin-angiotensin cascade. On the other hand,no evidence in this study can identify the enzyme responsible for Ang II generation. Although chymase has been the subject of greatest recent interest, alternative enzymes exist and could contribute.
The observations in this study confirm and extend earlier considerations that suggested a minimal role for bradykinin in the renal haemodynamic response to ACE-I in humans. 10, 22 Our earlier studies were performed on a low-salt diet, designed to activate the renin-angiotensin-system and potentially, therefore, minimise a contribution of kinins. In this study, performed on a high-salt diet to suppress the renin system, one consequence should have been enhancement of the relative contribution of kinins. Again, the renal haemodynamic response to candesartan exceeding substantially the response to captopril provides no support for a role for kinins in the response to captopril. Although some studies in animal models have suggested a role for kinins, there is compelling evidence for a species difference, in which a contribution of kinins to the renal haemodynamic response to ACE inhibition is substantial in the rat and dog, and is minimal in the rabbit and human. 22 Multiple lines of evidence suggest that intrarenal Ang II formation makes a substantial contribution, not only to normal salt and volume homeostasis, but also to the pathogenesis of disease in patients with diabetes mellitus and other forms of nephropathy, and in some patients with essential hypertension. 10 As most humans under most conditions operate on a salt intake substantially closer to the high-salt group in this study, than the low-salt group, the findings may be relevant to natural history and therapeutics. The non-ACE pathway appears to make a much more substantial contribution to total Ang II generation when salt intake is high, and thus therapeutic responses to the AT 1receptor blockers should be favourable when compared with the response to ACE inhibition.
